Composition, form of production and packaging
? Capsules hard gelatinous, the size в„–00, transparent; the contents of the capsules are white or white powder with a yellowish tint of color with crystalline particles.
glucosamine hydrochloride 500 mg
chondroitin sodium sulfate 400 mg
[PRING] stearic acid - 10 mg, magnesium stearate - 3 mg, manganese sulfate - 1 mg.
The composition of the gelatin capsule: gelatin - 120 mg.
30 pcs. - bottles of high-density polyethylene (1) - packs of cardboard.
60 pcs. - bottles of high-density polyethylene (1) - packs of cardboard.
100 pieces. - bottles of high-density polyethylene (1) - packs of cardboard.
120 pcs. - bottles of high-density polyethylene (1) - packs of cardboard.
200 pcs. - bottles of high-density polyethylene (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2017.
A drug that stimulates the regeneration of cartilaginous tissue.
Glucosamine hydrochloride and chondroitin sodium sulfate take part in the biosynthesis of connective tissue, helping to prevent cartilage destruction processes and stimulating tissue regeneration. The introduction of exogenous glucosamine enhances the production of the cartilage matrix and provides non-specific protection against chemical damage to the cartilage. Another possible action of glucosamine is the protection of the damaged cartilage from metabolic destruction caused by NSAIDs and SCS, as well as its own moderate anti-inflammatory effect.
Chondroitin sulfate serves as an additional substrate for the formation of a healthy cartilage matrix. Stimulates the formation of hyaluronan, the synthesis of proteoglycans and type II collagen, and also protects hyaluronan from enzymatic cleavage (by suppressing the activity of hyaluronidase); maintains the viscosity of the synovial fluid, stimulates mechanisms of cartilage repair and inhibits the activity of those enzymes (elastase, hyaluronidase) that break down the cartilage. In the treatment of osteoarthritis, it alleviates the symptoms of the disease and reduces the need for NSAIDs.
Bioavailability of glucosamine when ingested is 25% (due to the effect of "first passage" through the liver).
After absorption, radiolabeled glucosamine is first detected in the plasma and later penetrates into the tissue. The highest concentrations are found in the liver, kidneys and articular cartilage. About 30% of the dose is persistently persistent in bone and muscle tissue.
It is excreted mainly with urine in unchanged form, partly with feces. T 1/2 - 68 h.
When chondroitin sulfate is administered orally at a dose of 0.8 g (or 2 times / day 0.4 g), the plasma concentration increases for 24 hours. Absolute bioavailability is 12%.
It is metabolized by desulfurization.
It is excreted by the kidneys. T 1/2 - 310 min.
- degenerative-dystrophic diseases of joints and spine: osteoarthritis of I-III stage, osteochondrosis.
Inside. Adults and children over 15 years of age receive the first 3 weeks for 1 caps. 3 times / day; the next days - 1 caps. 2 times / day, regardless of food intake, with a small amount of water. The recommended duration of treatment is from 3 to 6 months.
If necessary, it is possible to conduct repeated courses of treatment, the duration of which is set individually.
Teraflex В® is well tolerated by patients.
From the digestive system: pain in the epigastric region, flatulence, diarrhea, constipation.
From the nervous system: dizziness, headache, drowsiness, insomnia.
From the cardiovascular system: tachycardia.
Other: allergic reactions, pain in the legs and peripheral edema.
- chronic renal failure of a serious degree;
- lactation period;
- age up to 15 years;
With caution should prescribe the drug for diabetes, a tendency to bleeding, bronchial asthma.
PREGNANCY AND LACTATION
Clinical data on the efficacy and safety of the use of Teraflex В® during pregnancy and during breastfeeding are absent.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in severe renal failure.
APPLICATION FOR CHILDREN
The use of the drug is contraindicated in children under the age of 15 years.
If there are side effects from the digestive system, the dose of the drug should be reduced 2 times, and in the absence of improvement - cancel the drug.
Cases of overdose are unknown.
Symptoms: with an overdose of chondroitin sulfate, hemorrhagic rash, nausea, vomiting are possible.
Treatment: gastric lavage, symptomatic therapy.
The drug improves the absorption of tetracyclines, reduces the effect of semisynthetic penicillins and chloramphenicol.
The drug is compatible with NSAIDs and GCS.
Chondroitin sulfate can enhance the action of anticoagulants.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of the reach of children at a temperature of 25 В° C. Shelf life - 3 years.